{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=40&state=North+Carolina", "query": { "state": "North Carolina", "city": "Durham", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 1938, "total_pages": 194, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=41&state=North+Carolina&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=39&state=North+Carolina&page_size=10" }, "source": "local", "last_synced_at": "2026-11-05T10:44:39.453Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07023289", "title": "A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Standard of Care", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2025-09-02", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T10:58:58.867Z", "location_count": 22, "location_summary": "Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07023289" }, { "nct_id": "NCT06616584", "title": "Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 378, "start_date": "2025-05-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T09:06:34.556Z", "location_count": 413, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06616584" }, { "nct_id": "NCT05563766", "title": "A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastroesophageal Junction Carcinoma" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2024-10-01", "completion_date": "2029-06-15", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T04:11:21.720Z", "location_count": 7, "location_summary": "Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563766" }, { "nct_id": "NCT05066217", "title": "An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lennox Gastaut Syndrome" ], "interventions": [ { "name": "Clemizole HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epygenix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Years to 55 Years" }, "enrollment_count": 260, "start_date": "2025-04-09", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T20:15:53.471Z", "location_count": 22, "location_summary": "Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05066217" }, { "nct_id": "NCT04065399", "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Mixed Lineage Acute Leukemia", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "cobicistat", "type": "DRUG" }, { "name": "revumenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 447, "start_date": "2019-11-05", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-05T10:44:39.453Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 17 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065399" }, { "nct_id": "NCT07421700", "title": "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Urothelial Cancer", "Urothelial Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab Vedotin", "type": "BIOLOGICAL" }, { "name": "PF-08634404", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2026-03-11", "completion_date": "2028-09-25", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T15:13:09.345Z", "location_count": 164, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 100 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Atascadero", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07421700" }, { "nct_id": "NCT07282678", "title": "Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression - Major Depressive Disorder", "Transcranial Alternating Current Stimulation" ], "interventions": [ { "name": "Closed-loop tACS", "type": "DEVICE" }, { "name": "Sham Comparator", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Pulvinar Neuro, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 214, "start_date": "2026-09", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T11:46:58.110Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07282678" }, { "nct_id": "NCT07227012", "title": "Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Carcinoma, Hepatocellular", "Hepatocellular Cancer", "Hepatocellular Carcinoma", "Liver Neoplasms", "Metastatic Hepatocellular Carcinoma", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "PF-08634404", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2025-12-01", "completion_date": "2028-10-17", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-21T13:47:58.716Z", "location_count": 46, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227012" }, { "nct_id": "NCT07222800", "title": "Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colonic Diseases", "Colorectal Neoplasms", "Digestive System Diseases", "Digestive System Neoplasms", "Gastrointestinal Diseases", "Gastrointestinal Neoplasms", "Intestinal Diseases", "Intestinal Neoplasms", "Neoplasms by Site", "Rectal Diseases" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "PF-08634404", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-12-11", "completion_date": "2031-08-17", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-03T21:21:33.011Z", "location_count": 254, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222800" }, { "nct_id": "NCT07165028", "title": "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatotic Liver Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Retatrutide", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4500, "start_date": "2025-10-15", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-03T21:57:34.792Z", "location_count": 141, "location_summary": "Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07165028" } ] }